Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial
Authors' conclusion
In high-risk people with diabetes, eGFR, UACR, and KDIGO category have different relationships to incident cardiovascular and kidney outcomes. The beneficial effect of efpeglenatide on these outcomes is independent of kidney-related risk category.
Study context
- Population
- High-risk people with T2D in the AMPLITUDE-O trial with baseline estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR); mean age 64.5 years
- Participants
- 3,983 people
- Comparison
- Lowest vs highest eGFR third; highest vs lowest UACR third; high- vs low-risk Kidney Disease Improving Global Outcomes (KDIGO) categories
- Primary endpoint
- Incidence of MACE and a composite kidney outcome across eGFR and UACR levels; whether efpeglenatide's effect varies with these indices
- Follow-up
- Median 1.8 years
Methodological detailsepidemiological analysis
- Epidemiological analysis
Primary result
As reported in the abstract
- Lowest eGFR third vs Highest eGFR third
- hazard (major adverse cardiovascular event (MACE)) 1.6 (95% CI 1.2–2.2)
- Lowest eGFR third vs Highest eGFR third
- hazard (kidney composite) 2.3 (95% CI 1.9–2.8)
- Highest UACR third vs Lowest UACR third
- hazard (MACE) 2.3 (95% CI 1.8–3.1)
- Highest UACR third vs Lowest UACR third
- hazard (kidney composite) 18.0 (95% CI 12.7–25.5)
- High-risk KDIGO category vs Low-risk KDIGO category
- hazard (MACE) 2.4 (95% CI 1.8–3.1)
- High-risk KDIGO category vs Low-risk KDIGO category
- hazard (kidney composite) 16.0 (95% CI 11.6–22.0)
Further findings
Efpeglenatide effect on MACE and kidney composite by kidney disease measure
- Efpeglenatide's effect on both outcomes did not vary with any kidney disease measure
- all interaction p values ≥0.26
Original publication
Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial. Diabetes Obes Metab. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →